NEW YORK (GenomeWeb News) – Bruker today provided updated financial guidance for fiscal year 2009, saying in a presentation at the Thomas Weisel Partners Healthcare Conference in Boston that it expects a year-over-year revenue decline of approximately 2 percent.

The firm had previously said that it expected flat to a low single-digit decline in revenues for the year.

Bruker also said that it is not likely to meet its previous goal of improving upon its 2008 earnings per share of $.45.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.